Skip to Content

Cabozantinib significantly prolongs PFS compared to sunitinib in papillary RCC

The results from SWOG 1500 were presented at ASCO GU 2021 and show that cabozantinib provides a statistically significant and clinically meaningful prolongation of progression-free survival compared to sunitinib in patients with metastatic papillary renal cell carcinoma.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top